Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Injective (INJ) To Rally Higher? Key Fractal Pattern Signals Potential Bullish Move

Injective (INJ) To Rally Higher? Key Fractal Pattern Signals Potential Bullish Move

CoinsProbeCoinsProbe2025/07/16 06:35
By:Nilesh Hembade

Date: Wed, July 16, 2025 | 05:56 AM GMT

The cryptocurrency market is deep in bullish territory, with Ethereum (ETH) riding the upside momentum, posting an impressive 19% gain over the week — now approaching the $3,150 mark. This strong uptrend is spilling over into major altcoins, and Injective (INJ) is starting to grab attention.

INJ has jumped 25% in the last seven days, boosting its 90-day performance to an impressive 68%. What’s catching even more attention now is the striking fractal pattern that INJ is forming — one previously seen in the bullish rally of Chainlink (LINK) from late 2024.

Injective (INJ) To Rally Higher? Key Fractal Pattern Signals Potential Bullish Move image 0 Source: Coinmarketcap

Fractal Suggests Bullish Reversal Ahead

Looking at Chainlink’s weekly chart from last year, we saw a series of lower highs forming a head-and-shoulders top, followed by a prolonged consolidation. LINK eventually bounced from a strong demand zone near $8.50, reclaimed both its 100- and 200-week moving averages, and launched into a stunning 106% rally, reaching as high as $30.

Injective (INJ) To Rally Higher? Key Fractal Pattern Signals Potential Bullish Move image 1 LINK and INJ Fractal Chart/Coinsprobe (Source: Tradingview)

Now, Injective appears to be echoing that same structure.

After weeks of range-bound price action and multiple rejections, INJ recently found support at its own demand zone near $9, similar to LINK’s earlier setup. From there, the token has surged to $13.16, and is now testing the 200-day moving average at $13.17 — the same trigger point where LINK exploded higher.

The chart shows nearly identical price behavior, including rounded tops, range compression, and a green breakout circle — hinting that history might repeat.

What’s Next for Injective (INJ)?

If INJ decisively breaks above the 200-day MA with volume, it could spark a fresh uptrend. The chart overlay projects a possible rally path — similar to LINK’s — which could take Injective above $20, representing a potential 50% upside from current levels.

While no fractal is perfect, crypto markets have a well-known habit of replaying previous structures, especially when overall sentiment is bullish — and that’s exactly what’s unfolding now.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales